Many clinical trials are now looking for eligible participants.
Open Oncology (cancer) Studies at the Vermont Cancer Center
Alzheimer's Disease Study:
Dr. William Pendlebury is conducting a study of Bapineuzumab, an investigational drug for the treatment of Alzheimer's Disease. For more information on this study contact Chris Ingvoldstad at (802)656-9912 or email: Christopher.Ingvoldstad@uvm.edu
The Insulin Resistance Intervention after Stroke Study:
The IRIS Trial is a randomized clinical trial that will test the effectiveness of a new approach to preventing stroke and heart attack among patients with a recent ischemic stroke or TIA. The new approach targets insulin resistance, a newly-recongnized cause of atherosclerosis. Atherosclerosis is the underlying disease that clogs vessels in strokes and heart attacks, Insulin resistance affects nearly half of all patients with stroke and TIA.
Participating stroke patients will be assigned to receive piogliatzone, a medication which reduces insulin resistance, or placebo (an inactive look-alike pill). Patients will stay on their assigned treatment for about four years. At the end of the study, investigators will compare the experience of patients on pioglitazone and placebo to see which group had fewer recurrent and heart attacks.
You can read more information about the IRIS Trial at http://www.iristrial.org;or contact Cathy Gregory, R.N. at (802) 656-9094, email: Cathy.Gregory@uvm.edu
